Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables: 2012-2025

Historic Change in Receivables for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $6.5 million.

  • Ptc Therapeutics' Change in Receivables fell 16.13% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 127.37%. This contributed to the annual value of -$1.7 million for FY2024, which is 212.54% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Change in Receivables of $6.5 million as of Q3 2025, which was up 129.56% from -$21.9 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Change in Receivables registered a high of $47.8 million during Q1 2025, and its lowest value of -$40.8 million during Q4 2024.
  • In the last 3 years, Ptc Therapeutics' Change in Receivables had a median value of -$8.1 million in 2023 and averaged $2.9 million.
  • Examining YoY changes over the last 5 years, Ptc Therapeutics' Change in Receivables showed a top increase of 1,166.07% in 2021 and a maximum decrease of 3,307.82% in 2021.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Change in Receivables stood at $16.4 million in 2021, then soared by 44.78% to $23.7 million in 2022, then crashed by 135.23% to -$8.3 million in 2023, then tumbled by 388.27% to -$40.8 million in 2024, then decreased by 16.13% to $6.5 million in 2025.
  • Its Change in Receivables stands at $6.5 million for Q3 2025, versus -$21.9 million for Q2 2025 and $47.8 million for Q1 2025.